Vascular Biogenics Ltd (VBLT)

[staccani]

After all I think VB111 could become Avastin more effective replacement in all Avastin indications and maybe more as monotherapy but most likely in combination (as VB111 inhibits tumor grwoth, then you need something to kill or help the immune system kill what is already there, either chemo or a checkpoint inhibitor or TIL's, vaccine etc etc).

Only rGBM could in fact could mean $2-3B annual revenue for VBLT (15,000 patients per annum at $150,000 each) ie $10-15B market cap or $250-$400 PPS including some dilution... and GBM is relatively rare cancer as far as incidence is concerned.

Imagine what could happen if VB111 is proven effective in CRC, NSCLC , ie the big killers...